Survival trends in glioblastoma and association with treating facility volume

Sonikpreet Aulakh, Michelle R. DeDeo, Joseph Free, Steven Rosenfeld, Alfredo Quinones-Hinojosa, Aneel Paulus, Alak Manna, Rami Manochakian, Asher A Chanan Khan, Sikander Ailawadhi

Research output: Contribution to journalArticle

Abstract

Glioblastoma (GBM) is one of the most lethal cancers. Various prognostic factors impact the survival of GBM patients. To further understand this extremely poor prognosis disease, we evaluated the effect of the treatment facility volumes on overall survival (OS) over the years, especially after the approval of multimodality therapy using temozolomide (TMZ) in 2005. National Cancer Data Base (NCDB) was utilized to identify GBM cases from 2004 through 2013 using ICD-O-3 code 9440/3 to identify eligible patients. We focused on studying the association between treatment facility volume and OS after adjusting for the patient-, disease-, and facility-characteristics. A total of 60,672 eligible GBM patients with median age of 65 years, treated at 1166 facilities were included in this analysis. The median annual facility volume was 3 patients/year (range: 0.1–55.1) and median OS was 8.1 months. There was an improvement in OS across all facilities after 2005, when multimodality therapy with TMZ was approved. Treatment at quartile 4 centers (Q4; >7 patients/year) was independently associated with decreased all-cause mortality in a multivariate analysis (Q3 hazard ratio [HR]: 1.11, 95% CI 1.09, 1.13; Q2 HR: 1.15, 95% CI 1.12, 1.19; Q1 HR: 1.25, 95% CI 1.17, 1.33). Treatment facility volume independently affects OS among GBM patients. Factors that are variable in high- and low-volume centers should be addressed to mitigate outcome disparities.

Original languageEnglish (US)
JournalJournal of Clinical Neuroscience
DOIs
StatePublished - Jan 1 2019

Fingerprint

Glioblastoma
temozolomide
Survival
Therapeutics
Neoplasms
Multivariate Analysis
Databases
Mortality

Keywords

  • Facility volume
  • Glioblastoma
  • Mortality
  • National cancer data base
  • Quartiles
  • Survival
  • Temozolomide

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Survival trends in glioblastoma and association with treating facility volume. / Aulakh, Sonikpreet; DeDeo, Michelle R.; Free, Joseph; Rosenfeld, Steven; Quinones-Hinojosa, Alfredo; Paulus, Aneel; Manna, Alak; Manochakian, Rami; Chanan Khan, Asher A; Ailawadhi, Sikander.

In: Journal of Clinical Neuroscience, 01.01.2019.

Research output: Contribution to journalArticle

@article{1c6968f4cae34ad6bc93e548edf1766f,
title = "Survival trends in glioblastoma and association with treating facility volume",
abstract = "Glioblastoma (GBM) is one of the most lethal cancers. Various prognostic factors impact the survival of GBM patients. To further understand this extremely poor prognosis disease, we evaluated the effect of the treatment facility volumes on overall survival (OS) over the years, especially after the approval of multimodality therapy using temozolomide (TMZ) in 2005. National Cancer Data Base (NCDB) was utilized to identify GBM cases from 2004 through 2013 using ICD-O-3 code 9440/3 to identify eligible patients. We focused on studying the association between treatment facility volume and OS after adjusting for the patient-, disease-, and facility-characteristics. A total of 60,672 eligible GBM patients with median age of 65 years, treated at 1166 facilities were included in this analysis. The median annual facility volume was 3 patients/year (range: 0.1–55.1) and median OS was 8.1 months. There was an improvement in OS across all facilities after 2005, when multimodality therapy with TMZ was approved. Treatment at quartile 4 centers (Q4; >7 patients/year) was independently associated with decreased all-cause mortality in a multivariate analysis (Q3 hazard ratio [HR]: 1.11, 95{\%} CI 1.09, 1.13; Q2 HR: 1.15, 95{\%} CI 1.12, 1.19; Q1 HR: 1.25, 95{\%} CI 1.17, 1.33). Treatment facility volume independently affects OS among GBM patients. Factors that are variable in high- and low-volume centers should be addressed to mitigate outcome disparities.",
keywords = "Facility volume, Glioblastoma, Mortality, National cancer data base, Quartiles, Survival, Temozolomide",
author = "Sonikpreet Aulakh and DeDeo, {Michelle R.} and Joseph Free and Steven Rosenfeld and Alfredo Quinones-Hinojosa and Aneel Paulus and Alak Manna and Rami Manochakian and {Chanan Khan}, {Asher A} and Sikander Ailawadhi",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jocn.2019.04.028",
language = "English (US)",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Survival trends in glioblastoma and association with treating facility volume

AU - Aulakh, Sonikpreet

AU - DeDeo, Michelle R.

AU - Free, Joseph

AU - Rosenfeld, Steven

AU - Quinones-Hinojosa, Alfredo

AU - Paulus, Aneel

AU - Manna, Alak

AU - Manochakian, Rami

AU - Chanan Khan, Asher A

AU - Ailawadhi, Sikander

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Glioblastoma (GBM) is one of the most lethal cancers. Various prognostic factors impact the survival of GBM patients. To further understand this extremely poor prognosis disease, we evaluated the effect of the treatment facility volumes on overall survival (OS) over the years, especially after the approval of multimodality therapy using temozolomide (TMZ) in 2005. National Cancer Data Base (NCDB) was utilized to identify GBM cases from 2004 through 2013 using ICD-O-3 code 9440/3 to identify eligible patients. We focused on studying the association between treatment facility volume and OS after adjusting for the patient-, disease-, and facility-characteristics. A total of 60,672 eligible GBM patients with median age of 65 years, treated at 1166 facilities were included in this analysis. The median annual facility volume was 3 patients/year (range: 0.1–55.1) and median OS was 8.1 months. There was an improvement in OS across all facilities after 2005, when multimodality therapy with TMZ was approved. Treatment at quartile 4 centers (Q4; >7 patients/year) was independently associated with decreased all-cause mortality in a multivariate analysis (Q3 hazard ratio [HR]: 1.11, 95% CI 1.09, 1.13; Q2 HR: 1.15, 95% CI 1.12, 1.19; Q1 HR: 1.25, 95% CI 1.17, 1.33). Treatment facility volume independently affects OS among GBM patients. Factors that are variable in high- and low-volume centers should be addressed to mitigate outcome disparities.

AB - Glioblastoma (GBM) is one of the most lethal cancers. Various prognostic factors impact the survival of GBM patients. To further understand this extremely poor prognosis disease, we evaluated the effect of the treatment facility volumes on overall survival (OS) over the years, especially after the approval of multimodality therapy using temozolomide (TMZ) in 2005. National Cancer Data Base (NCDB) was utilized to identify GBM cases from 2004 through 2013 using ICD-O-3 code 9440/3 to identify eligible patients. We focused on studying the association between treatment facility volume and OS after adjusting for the patient-, disease-, and facility-characteristics. A total of 60,672 eligible GBM patients with median age of 65 years, treated at 1166 facilities were included in this analysis. The median annual facility volume was 3 patients/year (range: 0.1–55.1) and median OS was 8.1 months. There was an improvement in OS across all facilities after 2005, when multimodality therapy with TMZ was approved. Treatment at quartile 4 centers (Q4; >7 patients/year) was independently associated with decreased all-cause mortality in a multivariate analysis (Q3 hazard ratio [HR]: 1.11, 95% CI 1.09, 1.13; Q2 HR: 1.15, 95% CI 1.12, 1.19; Q1 HR: 1.25, 95% CI 1.17, 1.33). Treatment facility volume independently affects OS among GBM patients. Factors that are variable in high- and low-volume centers should be addressed to mitigate outcome disparities.

KW - Facility volume

KW - Glioblastoma

KW - Mortality

KW - National cancer data base

KW - Quartiles

KW - Survival

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85065924890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065924890&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2019.04.028

DO - 10.1016/j.jocn.2019.04.028

M3 - Article

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

ER -